IDenta Corp. (IDTA)
USD 0.36
(0.0%)
USD 0.36
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 14.64 Thousand USD | -91.0% |
| 2022 | 162.71 Thousand USD | 135.19% |
| 2021 | 69.18 Thousand USD | -80.48% |
| 2020 | 354.44 Thousand USD | 440.99% |
| 2019 | 65.51 Thousand USD | -54.14% |
| 2018 | 142.86 Thousand USD | 183.29% |
| 2017 | -171.53 Thousand USD | 61.93% |
| 2016 | -450.51 Thousand USD | 8.07% |
| 2015 | -490.04 Thousand USD | 23.64% |
| 2014 | -641.72 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 79.9 Thousand USD | -53.28% |
| 2024 Q1 | 171.01 Thousand USD | 22.44% |
| 2023 FY | 14.64 Thousand USD | -91.0% |
| 2023 Q4 | 139.66 Thousand USD | 711.58% |
| 2023 Q3 | -22.83 Thousand USD | 70.08% |
| 2023 Q1 | -25.55 Thousand USD | -114.77% |
| 2023 Q2 | -76.33 Thousand USD | -198.72% |
| 2022 Q2 | 7488.00 USD | 117.67% |
| 2022 FY | 162.71 Thousand USD | 135.19% |
| 2022 Q4 | 173.05 Thousand USD | 791.15% |
| 2022 Q3 | 19.41 Thousand USD | 159.33% |
| 2022 Q1 | -42.36 Thousand USD | -92.25% |
| 2021 Q3 | -45.79 Thousand USD | -140.61% |
| 2021 Q2 | 112.77 Thousand USD | 63.12% |
| 2021 FY | 69.18 Thousand USD | -80.48% |
| 2021 Q4 | -22.03 Thousand USD | 51.88% |
| 2021 Q1 | 69.13 Thousand USD | 171.79% |
| 2020 Q4 | -96.3 Thousand USD | -134.0% |
| 2020 FY | 354.44 Thousand USD | 440.99% |
| 2020 Q1 | 72.47 Thousand USD | 506.59% |
| 2020 Q2 | 96.42 Thousand USD | 33.05% |
| 2020 Q3 | 283.23 Thousand USD | 193.74% |
| 2019 Q3 | 44.95 Thousand USD | 18.01% |
| 2019 Q1 | -3039.00 USD | -105.84% |
| 2019 FY | 65.51 Thousand USD | -54.14% |
| 2019 Q4 | -17.82 Thousand USD | -139.65% |
| 2019 Q2 | 38.09 Thousand USD | 1353.47% |
| 2018 Q3 | 97.86 Thousand USD | 4255.27% |
| 2018 FY | 142.86 Thousand USD | 183.29% |
| 2018 Q4 | 52.03 Thousand USD | -46.83% |
| 2018 Q2 | 2247.00 USD | -81.32% |
| 2018 Q1 | 12.02 Thousand USD | 126.33% |
| 2017 FY | -171.53 Thousand USD | 61.93% |
| 2017 Q1 | -7279.00 USD | 0.0% |
| 2017 Q2 | -61.88 Thousand USD | -750.23% |
| 2017 Q3 | -50.53 Thousand USD | 18.35% |
| 2017 Q4 | -45.66 Thousand USD | 9.63% |
| 2016 FY | -450.51 Thousand USD | 8.07% |
| 2015 FY | -490.04 Thousand USD | 23.64% |
| 2014 FY | -641.72 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.41 Million USD | 101.039% |
| Arrayit Corporation | -3.31 Million USD | 100.442% |
| Atlantic International Corp. | -5.62 Million USD | 100.26% |
| Biocept, Inc. | -32.08 Million USD | 100.046% |
| Bioqual, Inc. | 483.48 Thousand USD | 96.971% |
| CardioGenics Holdings Inc | -1.91 Million USD | 100.764% |
| DermTech, Inc. | -100.88 Million USD | 100.015% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion USD | 99.999% |
| HTG Molecular Diagnostics, Inc. | -21.59 Million USD | 100.068% |
| iMD Companies, Inc. | -200.63 Thousand USD | 107.299% |
| Interpace Biosciences, Inc. | 802 Thousand USD | 98.174% |
| Integrative Health Technologies, Inc. | 38.68 Thousand USD | 62.149% |
| InVitro International | 1553.00 USD | -842.949% |
| Lumos Diagnostics Holdings Limited | -8.59 Million USD | 100.17% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 125.2% |
| Medical Imaging Corp. | -3.02 Million USD | 100.484% |
| NovelStem International Corp. | -4.18 Million USD | 100.35% |
| Optigenex Inc. | -2.89 Million USD | 100.505% |
| PharmChem, Inc. | 845.1 Thousand USD | 98.267% |
| Proteome Sciences plc | -2.44 Million USD | 100.599% |
| Response Genetics, Inc | -20.18 Million USD | 100.073% |
| Rennova Health, Inc. | -3.29 Million USD | 100.445% |
| RushNet, Inc. | -607.02 Thousand USD | 102.412% |
| ScreenPro Security Inc. | -2.24 Million USD | 100.651% |
| Stella Diagnostics Inc. | -5.7 Million USD | 100.257% |
| StageZero Life Sciences Ltd. | -11.41 Million USD | 100.128% |
| Todos Medical Ltd. | -24.99 Million USD | 100.059% |